N-[4-(2,4-dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide | 1355170-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: N-[4-(2,4-dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide
• 英文别名: N-[4-(2,4-dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepin-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide；N-[4-(2,4-Dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide；N-[4-(2,4-dioxo-8,9,10,11-tetrahydro-1H-benzo[i][1,5]benzodiazepin-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide
• CAS: 1355170-07-8
• 化学式: C₂₆H₂₄N₄O₆S
• 分子量: 520.566
• InChiKey: YXKNZIYPZMDKEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[4-(2,4-dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide 在 potassium carbonate 、 苯硫酚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以55%的产率得到5-(4-methylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione
  参考文献：
  名称：

  P2X4 RECEPTOR ANTAGONIST

  摘要：

  公开号：

  EP2803662B1
• 作为产物：
  描述：

  5-(4-aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione 、 邻硝基苯磺酰氯 在 吡啶 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.0h， 生成 N-[4-(2,4-dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide
  参考文献：
  名称：

  P2X4 RECEPTOR ANTAGONIST

  摘要：

  公开号：

  EP2597088B1

文献信息

• P2X4 receptor antagonist
  申请人：Sakuma Shogo

  公开号：US08962613B2

  公开（公告）日：2015-02-24

  A diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof is used as A P2X4 receptor antagonist: wherein each of R21 and R22 is hydrogen, a C1-8 alkyl group or the like; R23 is hydrogen, a C1-8 alkyl group or the like; each of R24 and R25 is hydrogen, a C1-8 alkyl group or the like; R26 is hydrogen, a C1-8 alkyl group, a halogen atom, hydroxyl, nitro, cyano, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents or the like; and p is 0 or 1.

  具有以下式（III）或其药理学上可接受的盐的一种二氮平衍生物作为P2X4受体拮抗剂：其中R21和R22中的每一个是氢，C1-8烷基或类似物；R23是氢，C1-8烷基或类似物；R24和R25中的每一个是氢，C1-8烷基或类似物；R26是氢，C1-8烷基，卤素原子，羟基，硝基，氰基，苯基（可选地具有一个或多个取代基）或含有一个或多个取代基的杂环基或类似物；p为0或1。
• MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP3848051A1

  公开（公告）日：2021-07-14

  The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.

  本发明涉及一种用于预防或治疗痛觉疼痛、炎症性疼痛或神经病理性疼痛的药物，该药物作为活性成分包括具有P2X4受体拮抗剂作用的化合物、该化合物的同系物、其立体异构体、其药学上可接受的盐、其水合物或其溶液。该药物对驾驶或机器操作能力无影响，对汽车驾驶能力无影响，对从事危险机器操作（包括驾驶汽车）的患者用药无任何限制，或可对从事危险机器操作（包括驾驶汽车）的患者用药。
• MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：US20210121478A1

  公开（公告）日：2021-04-29

  A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof, or a hydrate or solvate thereof as an active ingredient.
• US8962613B2
  申请人：——

  公开号：US8962613B2

  公开（公告）日：2015-02-24
• US9382236B2
  申请人：——

  公开号：US9382236B2

  公开（公告）日：2016-07-05